{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:46Z","timestamp":1707524506926},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,20]]},"DOI":"10.7759\/cureus.24299","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T08:55:06Z","timestamp":1650444906000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study"],"prefix":"10.7759","author":[{"given":"Kapil D","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai B","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavan  K","family":"Reddy N","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khokan","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Bhapkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bini  M","family":"Thampi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.18203\/2349-2902.isj20203821","article-title":"Management of acute bacterial skin and skin structure infections in India: are we equipped to meet the challenges of the growing menace of methicillin-resistant Staphylococcus aureus?","volume":"7","author":"Mahakalkar C","year":"2020","unstructured":"Mahakalkar C, Padhye D, Nandagawali VR, Takale S, Ahdal J, Jain R. Management of acute bacterial skin and skin structure infections in India: are we equipped to meet the challenges of the growing menace of methicillin-resistant Staphylococcus aureus?. Int Surg J. 2020, 7:3172. 10.18203\/2349-2902.isj20203821","journal-title":"Int Surg J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1450-6","article-title":"Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs","volume":"11","author":"Falcone M","year":"2016","unstructured":"Falcone M, Concia E, Giusti M, Mazzone A, Santini C, Stefani S, Violi F. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Intern Emerg Med. 2016, 11:637-48. 10.1007\/s11739-016-1450-6","journal-title":"Intern Emerg Med"},{"key":"ref3","unstructured":"Acute bacterial skin and skin structure infections. developing drugs for treatment. Guidance for industry. (2013). Accessed: March 15, 2019: https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071185.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2017.1311398","article-title":"Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update","volume":"29","author":"Esposito S","year":"2017","unstructured":"Esposito S, Bassetti M, Concia E, et al.. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. J Chemother. 2017, 29:197-214. 10.1080\/1120009X.2017.1311398","journal-title":"J Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2014.12.001","article-title":"Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital","volume":"48","author":"Pollack CV Jr","year":"2015","unstructured":"Pollack CV Jr, Amin A, Ford WT Jr, et al.. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015, 48:508-19. 10.1016\/j.jemermed.2014.12.001","journal-title":"J Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix109","article-title":"Preventing methicillin-resistant Staphylococcus aureus (MRSA) disease in Urban US hospitals-now for the hard part: More evidence pointing to the community as the source of MRSA acquisition","volume":"215","author":"Ray SM","year":"2017","unstructured":"Ray SM. Preventing methicillin-resistant Staphylococcus aureus (MRSA) disease in Urban US hospitals-now for the hard part: More evidence pointing to the community as the source of MRSA acquisition. J Infect Dis. 2017, 215:1631-3. 10.1093\/infdis\/jix109","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw828","article-title":"Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group","volume":"64","author":"Doernberg SB","year":"2017","unstructured":"Doernberg SB, Lodise TP, Thaden JT, et al.. Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis. 2017, 64:S24-9. 10.1093\/cid\/ciw828","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001974","article-title":"Antibiotic resistance in India: drivers and opportunities for action","volume":"13","author":"Laxminarayan R","year":"2016","unstructured":"Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: drivers and opportunities for action. PLoS Med. 2016, 13:e1001974. 10.1371\/journal.pmed.1001974","journal-title":"PLoS Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20192910","article-title":"Current clinical trends in the management of gram positive infections in Indian critical care settings: a survey","volume":"7","author":"Rampal R","year":"2019","unstructured":"Rampal R, Ahdal J, Kaushik K, Jain R. Current clinical trends in the management of gram positive infections in Indian critical care settings: a survey. Int J Res Med Sci. 2019, 7:2737. 10.18203\/2320-6012.ijrms20192910","journal-title":"Int J Res Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-mrsa benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"Bhagwat SS","year":"2019","unstructured":"Bhagwat SS, Nandanwar M, Kansagara A, et al.. Levonadifloxacin, a novel broad-spectrum anti-mrsa benzoquinolizine quinolone agent: review of current evidence. Drug Des Devel Ther. 2019, 13:4351-65. 10.2147\/DDDT.S229882","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000999","article-title":"In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms","volume":"68","author":"Tellis M","year":"2019","unstructured":"Tellis M, Joseph J, Khande H, Bhagwat S, Patel M. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms. J Med Microbiol. 2019, 68:1129-36. 10.1099\/jmm.0.000999","journal-title":"J Med Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu C","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al.. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011, 52:e18-55. 10.1093\/cid\/ciq146","journal-title":"Clin Infect Dis"},{"key":"ref13","unstructured":"FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. (year). (2021). Accessed. October 15, 2021: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-increased-risk-death-i...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2012.00043","article-title":"Intracellular Staphylococcus aureus: live-in and let die","volume":"2","author":"Fraunholz M","year":"2012","unstructured":"Fraunholz M, Sinha B. Intracellular Staphylococcus aureus: live-in and let die. Front Cell Infect Microbiol. 2012, 2:43. 10.3389\/fcimb.2012.00043","journal-title":"Front Cell Infect Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1178633720970569","article-title":"A systemic literature review and meta-analysis reporting the prevalence and impact of methicillin-resistant staphylococcus aureus infection in India","volume":"13","author":"Ghia CJ","year":"2020","unstructured":"Ghia CJ, Waghela S, Rambhad G. A systemic literature review and meta-analysis reporting the prevalence and impact of methicillin-resistant staphylococcus aureus infection in India. Infect Dis (Auckl). 2020, 13:1178633720970569. 10.1177\/1178633720970569","journal-title":"Infect Dis (Auckl)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/ijmm.IJMM_20_34","article-title":"A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin: Therapeutic role in nosocomial and community infections","volume":"37","author":"Bakthavatchalam YD","year":"2019","unstructured":"Bakthavatchalam YD, Rao SV, Isaac B, et al.. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin: Therapeutic role in nosocomial and community infections. Indian J Med Microbiol. 2019, 37:478-87. 10.4103\/ijmm.IJMM_20_34","journal-title":"Indian J Med Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001102","article-title":"Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations","volume":"68","author":"Dubois J","year":"2019","unstructured":"Dubois J, Dubois M. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019, 68:1716-22. 10.1099\/jmm.0.001102","journal-title":"J Med Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire S","year":"2011","unstructured":"Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011, 55:649-58. 10.1128\/AAC.01201-10","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages","volume":"50","author":"Barcia-Macay M","year":"2006","unstructured":"Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006, 50:841-51. 10.1128\/AAC.50.3.841-851.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa142","article-title":"Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital","volume":"75","author":"Bakthavatchalam YD","year":"2020","unstructured":"Bakthavatchalam YD, Shankar A, Muniyasamy R, et al.. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. J Antimicrob Chemother. 2020, 75:2156-9. 10.1093\/jac\/dkaa142","journal-title":"J Antimicrob Chemother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3188-3192.2004","article-title":"Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents","volume":"48","author":"Peric M","year":"2004","unstructured":"Peric M, Jacobs MR, Appelbaum PC. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother. 2004, 48:3188-92. 10.1128\/AAC.48.8.3188-3192.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","article-title":"Efficacy and safety of a novel broad-spectrum anti-MRSA Agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a phase 3, open label, randomized study","volume":"68","author":"Bhatia A","year":"2020","unstructured":"Bhatia A, Mastim M, Shah M, et al.. Efficacy and safety of a novel broad-spectrum anti-MRSA Agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a phase 3, open label, randomized study. J Assoc Physicians India. 2020, 68:30-6.","journal-title":"J Assoc Physicians India"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O'Riordan W","year":"2018","unstructured":"O'Riordan W, McManus A, Teras J, et al.. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018, 67:657-66. 10.1093\/cid\/ciy165","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz396","article-title":"Omadacycline for acute bacterial skin and skin structure infections","volume":"69","author":"Abrahamian FM","year":"2019","unstructured":"Abrahamian FM, Sakoulas G, Tzanis E, et al.. Omadacycline for acute bacterial skin and skin structure infections. Clin Infect Dis. 2019, 69:S23-32. 10.1093\/cid\/ciz396","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009163","article-title":"Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: subgroup analysis of 2 randomized phase 3 trials","volume":"96","author":"De Anda C","year":"2017","unstructured":"De Anda C, Anuskiewicz S, Prokocimer P, Vazquez J. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: subgroup analysis of 2 randomized phase 3 trials. Medicine (Baltimore). 2017, 96:e9163. 10.1097\/MD.0000000000009163","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis A","year":"2011","unstructured":"Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011, 120:103-10. 10.1159\/000334441","journal-title":"Cardiology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12594","article-title":"Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine fluoroquinolone","volume":"12","author":"Mason JW","year":"2019","unstructured":"Mason JW, Chugh R, Patel A, Gutte R, Bhatia A. Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine fluoroquinolone. Clin Transl Sci. 2019, 12:47-52. 10.1111\/cts.12594","journal-title":"Clin Transl Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.26226\/morressier.56d6be7ad462b80296c97cf4","article-title":"Electrocardiographic effects of WCK 2349","author":"Mason JW","year":"2016","unstructured":"Mason JW, Chugh R, Lakdavala F, Bhatia A. Electrocardiographic effects of WCK 2349. 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2016, 10.26226\/morressier.56d6be7ad462b80296c97cf4","journal-title":"26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/88753-real-world-evidence-of-efficacy-and-safety-of-levonadifloxacin-oral-and-iv-in-the-management-of-acute-bacterial-skin-and-skin-structure-infections-absssi-findings-of-a-retrospective-multi-center-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:01Z","timestamp":1707507421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/88753-real-world-evidence-of-efficacy-and-safety-of-levonadifloxacin-oral-and-iv-in-the-management-of-acute-bacterial-skin-and-skin-structure-infections-absssi-findings-of-a-retrospective-multi-center-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.24299","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,20]]}}}